Advances in Chronic Kidney Disease
Volume 12, Issue 1 , Pages 84-87 , January 2005

Deprivation and dialysis: Pathways to kidney failure in Australian Aborigines

  • Mark Thomas

      Affiliations

    • Department of Nephrology, Royal Perth Hospital, Perth, Australia.
    • Corresponding Author InformationAddress correspondence to Mark Thomas, MB, BS, FRACP, Department of Nephrology, Royal Perth Hospital, Box X2213, Perth, Western Australia 6001.

References 

  1. Spencer JL , Silva DT , Snelling P , Hoy WE . An epidemic of renal failure among Australian Aboriginals . Med J Aust . 1998;168:537–541
  2. Seymour AE . Glomerular disease in whites versus Australian aboriginals (‘last of a race in ruin’ (G.K. Chesterton)) . Nephrol Dial Transplant . 1995;10:769–770
  3. Young RJ , Hoy WE , Kincaid-Smith P , et al.   Glomerular size and glomerulosclerosis in Australian aborigines . Am J Kidney Dis . 2000;36:481–489
  4. Hughson M , Farris 3rd AB , Douglas-Denton R , et al.   Glomerular number and size in autopsy kidneys (The relationship to birth weight) . Kidney Int . 2003;63:2113–2122
  5. Baldwin DN , Spencer JL , Jeffries-Stokes CA . Carbohydrate intolerance and kidney stones in children in the Goldfields . J Paediatr Child Health . 2003;39:381–385
  6. Brameld K , Holman D , Thomas M , et al.   Use of a state data bank to measure incidence and prevalence of a chronic disease (End-stage renal failure) . Am J Kidney Dis . 1999;34:1033–1039
  7. McDonald SP , Russ GR . Incident ESRD rates for Aborigines and non-indigenous Australians in the late 1990s . In:  Russ GR editors. ANZDATA Registry Report 2001 . Adelaide, SA: Australia and New Zealand Dialysis and Transplant Registry; 2001;p. 95
  8. Australian Bureau of Statistics . Experimental Estimates of the Aboriginal and Torres Strait Islander Population, Australia, 1998 . 1998; Canberra, ABS Cat. No. 3230.0
  9. Cass A , Gillin AG , Horvath JS . End-stage renal disease in aboriginals in New South Wales (A very different picture to the Northern Territory) . Med J Aust . 1999;171:407–410
  10. Hoy WE , Mathews JD , McCredie DA , et al.   The multidimensional nature of renal disease (Rates and associations of albuminuria in an Australian Aboriginal community) . Kidney Int . 1998;54:1296–1304
  11. Gracey M , Spargo RM , Smith P , et al.   Risk factors for ill-health in a remote desert-dwelling aboriginal community in Western Australia . Aust N Z J Med . 1996;26:171–179
  12. McDermott R , Rowley KG , Lee AJ , et al.   Increase in prevalence of obesity and diabetes and decrease in plasma cholesterol in a central Australian aboriginal community . Med J Aust . 2000;172:480–484
  13. Beilin LJ , Puddey IB , Burke V . Lifestyle and hypertension . Am J Hypertens . 1999;12:934–945
  14. Stengel B , Tarver-Carr ME , Powe NR , et al.   Lifestyle factors, obesity and the risk of chronic kidney disease . Epidemiology . 2003;14:479–487
  15. Cass A , Cunningham J , Snelling P , et al.   Exploring the pathways leading from disadvantage to end-stage renal disease for indigenous Australians . Soc Sci Med . 2004;58:767–785
  16. Hoy WE , Wang Z , Baker PR , et al.   Reduction in natural death and renal failure from a systematic screening and treatment program in an Australian Aboriginal community . Kidney Int . 2003;63(suppl):S66–S73
  17. Baker PRA , Wang Z , Glaziou P , et al.   Cost-savings of a treatment program to reduce renal failure in Australian Aborigines . J Am Soc Nephrol . 2000;11:A0745; 33rd Annual Meeting of the American Society of Nephrology
  18. Hoy WE , Konsdalsamy Chennavesakan S . Resurgence of deaths and end-stage renal disease in a high risk Aboriginal Australian community . Nephrology . 2003;8:A59; 39th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology.
  19. Nakao N , Yoshimura A , Morita H , et al.   Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE) (a randomised controlled trial) . Lancet . 2003;361:117–124

 Dr. Thomas has received honoraria for lectures, research funding and conference attendance costs from a number of different pharmaceutical companies, including Amgen Australia, Astra-Zeneca, Boehringer Ingelheim, Fresenius Medical Care, Janssen-Cilag, Novartis, Sanofi-Synthelabo, Servier Laboratories, and Solvay Pharmaceuticals.

PII: S1548-5595(04)00180-6

doi: 10.1053/j.ackd.2004.10.008

Advances in Chronic Kidney Disease
Volume 12, Issue 1 , Pages 84-87 , January 2005

Article Tools

* Image Usage & Resolution